{
  "url": "https://struct.news/briefs/viridians-revenue-jumped-279-its-operating-loss-still-widened",
  "title": "Viridian’s revenue jumped 279%. Its operating loss still widened.",
  "summary": "R&D spending fell $15.0 million in the three months ended June 30, even as net loss widened to $127.1 million.",
  "published_at": "2026-08-06T12:02:14.928451+00:00",
  "publisher": "Struct",
  "usage": "Figures are as reported by the company. Quote with attribution to the source filing.",
  "company": {
    "name": "Viridian Therapeutics, Inc.",
    "ticker": "VRDN",
    "cik": "1590750",
    "sector": "Healthcare",
    "industry": "Biotechnology"
  },
  "source_filing": {
    "form": "10-Q",
    "filed": "2026-08-06",
    "accession": "0001590750-26-000018",
    "url": "https://www.sec.gov/Archives/edgar/data/1590750/000159075026000018/vrdn-20260630.htm"
  },
  "comparison_filing": {
    "form": "10-Q",
    "filed": "2025-08-06",
    "url": "https://www.sec.gov/Archives/edgar/data/1590750/000159075025000012/vrdn-20250630.htm"
  },
  "reported_figures": [
    {
      "group": "The filing in three numbers",
      "label": "Revenue",
      "value": 70849000,
      "display": "$70.8M",
      "unit": "usd",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "sec_filing",
        "label": "Filed company results",
        "form": "10-Q",
        "accession": "0001590750-26-000018",
        "filing_date": "2026-08-06"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Revenue YoY",
      "value": 23359.933774834437,
      "display": "+23359.9%",
      "unit": "percent",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001590750-26-000018",
        "filing_date": "2026-08-06"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Operating margin",
      "value": -512.9147906110178,
      "display": "-512.9%",
      "unit": "percent",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001590750-26-000018",
        "filing_date": "2026-08-06"
      }
    }
  ],
  "watch_next": [
    {
      "type": "liquidity_financing",
      "statement": "Viridian disclosed a Hercules loan maturity date of October 1, 2026, making the next financing-status disclosure a specific balance-sheet item to compare.",
      "importance": "high",
      "evidence": "Under the Hercules First Amendment, the maturity date was extended to October 1, 2026 and the Lenders provided the Borrower access to an increased term loan with an aggregate principal amount of up to $150.0 million",
      "source_date": "2026-08-06"
    },
    {
      "type": "product_pipeline",
      "statement": "TED portfolio costs fell as phase 3 trial timing and stage reduced clinical-trial and manufacturing spending, while other research and personnel costs increased.",
      "importance": "medium",
      "evidence": "Direct costs related to the TED portfolio decreased by $19.7 million during the three months ended June 30, 2026 compared to the three months ended June 30, 2025, primarily driven by a decrease in clinical trial and manufacturing associated costs due to the timing and stage of our phase 3 clinical trials for veligrotug.",
      "source_date": "2026-08-06"
    }
  ],
  "related_tickers": [
    "VRDN"
  ],
  "disclaimer": "Descriptive reporting of filed results. Not investment advice, and contains no forecast or recommendation."
}